Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers

Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers

Introduction: RTS,S/AS01 is currently the most advanced malaria vaccine but provides incomplete, short-term protection. It was developed for use within the expanded program on immunizations (EPI) for African children. Another use could be adding mass RTS,S/AS01 vaccination to the integrated malaria...

Full description

Bibliographic Details
Main Authors: Lorenz von Seidlein, Borimas Hanboonkunupakarn, Podjanee Jittamala, Pongphaya Pongsuwan, Kesinee Chotivanich, Joel Tarning, Richard M. Hoglund, Markus Winterberg, Mavuto Mukaka, Pimnara Peerawaranun, Pasathorn Sirithiranont, Zoe Doran, Christian F. Ockenhouse, Karen Ivinson, Cynthia Lee, Ashley J. Birkett, David C. Kaslow, Pratap Singhasivanon, Nicholas P.J. Day, Arjen M. Dondorp, Nicholas J. White, Sasithon Pukrittayakamee
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
malaria
vaccine
rts
s/as01
p. falciparum
phase 2
elisa pharmacokinetics
dihydroartemisinin
piperaquine
primaquine
Online Access:http://dx.doi.org/10.1080/21645515.2019.1643675

Internet

http://dx.doi.org/10.1080/21645515.2019.1643675

Similar Items